Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 13TCr 12TCr 11TCr 9.98TCr 19TCr 12,09900Cr 20TCr 1,33300Cr 53TCr 6,60500Cr 49TCr 48TCr 20,70200Cr P/E 2026 *
35.9x
P/E 2027 * 29.6x
Enterprise Value 13TCr 12TCr 11TCr 9.77TCr 18TCr 11,84400Cr 19TCr 1,30500Cr 52TCr 6,46500Cr 48TCr 47TCr 20,26400Cr EV / Sales 2026 *
9.64x
EV / Sales 2027 * 8.35x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day-1.08%
1 week-4.38%
Current month-7.85%
1 month-1.81%
3 months-6.03%
6 months+18.79%
Current year+13.60%
1 week 513.8
Extreme 513.8
549.56
1 month 509.2
Extreme 509.205
568.67
Current year 412.27
Extreme 412.27
568.67
1 year 412.27
Extreme 412.27
568.67
3 years 346.28
Extreme 346.285
568.67
5 years 179.96
Extreme 179.96
568.67
10 years 71.46
Extreme 71.46
568.67
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2020
Director of Finance/CFO 57 10/04/2019
Chief Tech/Sci/R&D Officer - 01/07/2025
Director TitleAgeSince
Director/Board Member 66 01/01/1998
Chairman 70 01/05/2012
Director/Board Member 57 18/06/2015
Date Insider Type Main position Quantity % Market Cap. Importance
20/10/26 Free

Director

795 0.0003%
15/10/26 Free

Director

29 0.0000%
15/10/26 Free

Director

93 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%-4.38%+20.68%+45.17% 13TCr
-0.30%-6.68%+27.12%+127.32% 1,20000Cr
+1.25%-5.35%+32.65%+78.98% 65TCr
+0.94%-2.99%+21.13%+106.30% 51TCr
-0.60%-1.95%+25.73%+67.00% 38TCr
+0.69%-9.50%+36.78%+30.83% 33TCr
+0.41%-4.70%+24.18%+50.18% 29TCr
+0.81%-4.08%-2.95%+31.59% 27TCr
-0.15%-6.45%+29.06%+65.76% 24TCr
-0.06%-0.98%+31.42%+122.83% 21TCr
Average +0.19%-4.72%+24.58%+72.60% 42TCr
Weighted average by Cap. +0.26%-5.17%+25.86%+86.55%

Financials

2026 *2027 *
Net sales 1.33TCr 1.21TCr 1.11TCr 1.01TCr 1.9TCr 1,22800Cr 2TCr 14TCr 5.38TCr 67TCr 4.97TCr 4.87TCr 2,10200Cr 1.47TCr 1.34TCr 1.23TCr 1.12TCr 2.1TCr 1,35800Cr 2.21TCr 15TCr 5.95TCr 74TCr 5.5TCr 5.38TCr 2,32300Cr
Net income 365.9Cr 333.63Cr 307.19Cr 279.6Cr 524.88Cr 34TCr 552.61Cr 3.74TCr 1.49TCr 19TCr 1.37TCr 1.34TCr 58TCr 451.86Cr 412.01Cr 379.36Cr 345.28Cr 648.19Cr 42TCr 682.43Cr 4.61TCr 1.83TCr 23TCr 1.7TCr 1.66TCr 72TCr
Net Debt -275.88Cr -251.55Cr -231.61Cr -210.81Cr -395.75Cr -26TCr -416.65Cr -2.82TCr -1.12TCr -14TCr -1.03TCr -1.01TCr -44TCr -816.21Cr -744.23Cr -685.25Cr -623.7Cr -1.17TCr -76TCr -1.23TCr -8.33TCr -3.31TCr -41TCr -3.06TCr -3TCr -1,29400Cr
Projected Income Statement - Annual - Vertex Pharmaceuticals Incorporated
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
20/26/20 $515.02 -1.08% 17,67,923
19/26/19 $520.66 -2.94% 11,77,432
18/26/18 $536.45 +0.42% 12,92,403
17/26/17 $534.20 -0.67% 15,12,600
16/26/16 $537.79 -0.15% 12,24,717
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Vertex Pharmaceuticals Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
515.02USD
Average target price
595.36USD
Spread / Average Target
+15.60%
  1. Stock Market
  2. Stocks
  3. VRTX Stock
BLACK FRIDAY -Get 40% off all subscriptions
BLACK FRIDAY40% off all subscriptions
Get the offer